ストックスクリーナーアプリを入手
1.87
12.65%
0.21
アフターアワーズ：
1.90
0.03
+1.60%
前日終値:
$1.66
開ける：
$1.69
24時間の取引高:
80,420
Relative Volume:
1.04
時価総額：
$3.15M
収益：
-
当期純損益:
$-11.28M
株価収益率:
-0.6213
EPS:
-3.01
ネットキャッシュフロー:
$-9.78M
1週間 パフォーマンス:
-16.52%
1か月 パフォーマンス:
-45.80%
6か月 パフォーマンス:
-76.87%
1年 パフォーマンス:
-76.96%
1日の値動き範囲:
$1.6776
$1.90
1週間の範囲:
$1.62
$2.10
52週間の値動き範囲:
$1.62
$14.67
Ensysce Biosciences Inc Stock (ENSC) Company Profile
名前
Ensysce Biosciences Inc
セクター
電話
(858) 263-4196
住所
7946 IVANHOE AVENUE, LA JOLLA
ENSC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ENSC
Ensysce Biosciences Inc
|
1.87 | 3.15M | 0 | -11.28M | -9.78M | -3.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.47 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.49 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
599.87 | 36.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.75 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
252.77 | 25.74B | 3.81B | -644.79M | -669.77M | -6.24 |
Ensysce Biosciences Inc (ENSC) 最新ニュース
Ensysce Biosciences files to sell 652,439 shares of common stock for holders - MSN
ENSC stock touches 52-week low at $1.7 amid market challenges By Investing.com - Investing.com South Africa
ENSC stock touches 52-week low at $1.7 amid market challenges - Investing.com UK
Comparing Ensysce Biosciences (NASDAQ:ENSC) & MacroGenics (NASDAQ:MGNX) - Defense World
Ensysce Biosciences Stock Price, Quotes and Forecasts | NASDAQ:ENSC - Benzinga
Ensysce Biosciences (ENSC) Plans to Sell Over 650,000 Shares - GuruFocus
Ensysce Biosciences completes key trial phase for safer opioid - Investing.com
Ensysce Biosciences completes key trial phase for safer opioid By Investing.com - Investing.com India
Revolutionary Opioid Drug Shows Breakthrough Overdose Protection in Clinical Trial - Stock Titan
Ensysce Biosciences Stock Rises On Positive Data From Opioid Overdose Protection Study: Retail’s Thrilled - MSN
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
ENSC stock touches 52-week low at $2.11 amid market challenges - Investing.com
After-Hour Gains For Ensysce Biosciences (ENSC) Signal Renewed Interest - Stocks Telegraph
Ensysce Biosciences Secures $1.1 Million in Registered Direct Offering, Prices 315,188 Shares at $3.49 per Share - AInvest
Ensysce Biosciences corrects SEC filing omission By Investing.com - Investing.com South Africa
Ensysce Biosciences corrects SEC filing omission - Investing.com
Ensysce Biosciences raises $1.1 million in stock sale By Investing.com - Investing.com South Africa
Ensysce Biosciences raises $1.1 million in stock sale - Investing.com
Ensysce Raises Fresh Capital: Strategic $1.1M Investment Powers Next-Gen Pain Drug Pipeline - Stock Titan
Ensysce Biosciences Reminds Shareholders to Vote At Upcoming 2022 Virtual Annual Shareholder Meeting - ACCESS Newswire
(ENSC) On The My Stocks Page - news.stocktradersdaily.com
Ensysce Biosciences Advances in Opioid Innovation - TipRanks
Revolutionary Opioid Safety Technology Takes Center Stage at PAINWeek 2025 - StockTitan
How the (ENSC) price action is used to our Advantage - news.stocktradersdaily.com
Ensysce Biosciences (ENSC) Projected to Post Earnings on Friday - Defense World
Zacks Small Cap Issues Negative Forecast for ENSC Earnings - Defense World
Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC) - EIN News
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
When Will Ensysce Biosciences, Inc. (NASDAQ:ENSC) Breakeven? - Simply Wall St
Ensysce Biosciences Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
Ensysce Biosciences, Inc. SEC 10-K Report - TradingView
Ensysce Biosciences Narrows Losses to $8M, Secures FDA Breakthrough Status - StockTitan
(ENSC) Long Term Investment Analysis - Stock Traders Daily
Ensysce Biosciences to Present Pain Management Innovations at ROTH Conference - StockTitan
Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids - Marketscreener.com
Ensysce Biosciences Releases Updated Investor Presentation Available Via Investor Relations Website - ACCESS Newswire
Ensysce Biosciences Provides Business Update and Reports First Quarter 2022 Financial Results - ACCESS Newswire
Ensysce Biosciences Regains Compliance with Nasdaq - ACCESS Newswire
Ensysce Biosciences Announces Pricing of $4.1 Million Public Offering - ACCESS Newswire
How To Trade (ENSC) - Stock Traders Daily
Revolutionary Pain Management: This New Opioid Actually Prevents Overdose - StockTitan
When Can We Expect A Profit From Ensysce Biosciences, Inc. (NASDAQ:ENSC)? - Yahoo Finance
Ensysce Biosciences Announces Fourth Quarter and Full Year 2021 Earnings Release Date and Timing of Corporate Update Call - ACCESS Newswire
Ensysce Biosciences Announces Key Efficacy Data for Lead Analgesic - ACCESS Newswire
Ensysce Biosciences Provides Key Themes Following IASP 2024 Symposium - ACCESS Newswire
Ensysce Biosciences Receives Positive Nasdaq Listing Determination - ACCESS Newswire
Ensysce Biosciences Releases Updated Investor Presentation Ahead of Corporate Update Call - ACCESS Newswire
Ensysce Biosciences Inc (ENSC) 財務データ
収益
当期純利益
現金流量
EPS
1.00%
大文字化:
|
ボリューム (24 時間):